1. Does the volume of ductal carcinoma in situ impact the positive margin rate in patients undergoing breast conservation for invasive breast cancer?
Martin-Dunlap TM, Cyr AE, Al Mushawah F, Gao F, Margenthaler JA.
J Surg Res. 2013 Sep
2. Compromised margins following mastectomy for stage I-III invasive breast cancer.
Yu J, Al Mushawah F, Taylor ME, Cyr AE, Gillanders WE, Aft RL, Eberlein TJ, Gao F, Margenthaler JA. J Surg Res. 2012 Sep
3. Positive margin rates following breast-conserving surgery for stage I-III breast cancer: palpable versus nonpalpable tumors.
Atkins J, Al Mushawah F, Appleton CM, Cyr AE, Gillanders WE, Aft RL, Eberlein TJ, Gao F, Margenthaler JA. J Surg Res. 2012 Sep
4. Metastatic Invasive Breast Cancer Recurrence Following Curative-Intent Therapy for Ductal Carcinoma In Situ.
Al Mushawah F, Rastelli A, Pluard T, Margenthaler JA.
J Surg Res. 2011 May 23.
5. Axillary staging prior to or after neoadjuvant systemic therapy? A single institutional experience.
ALMushawah F, Tan MC, Margenthaler JA.
J Surg Oncol. 2010 Oct 1; 102(5):404-7.
6. Residual nodal disease in biopsy proven n1/n2 breast cancer following neoadjuvant systemic therapy.
Al Mushawah F, Tan MC, Margenthaler JA.
World J Surg. 2010 Feb; 34(2):256-60.
7. Predictors of complete pathological response after neoadjuvant systemic therapy for breast cancer.
Tan MC, Al Mushawah F, Gao F, Aft RL, Gillanders WE, Eberlein TJ, Margenthaler JA.
Am J Surg. 2009 Oct; 198(4):520-5.
Book Chapter:
Al- Mushawah Fatema and Aft R. (Updates on The Surgical Management of Breast cancer: Areas of Controversy and Advancement), Emerging Cancer Therapeutics, Breast Cancer, 2010.
